Ewen D. D. Calder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ewen D. D. Calder has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Sutherland
School of Chemistry, Glasgow University, Glasgow, G12 8QQ, UK
9 shared publications - Ester M. Hammond
Department of Oncology, University of Oxford, Oxford, UK
6 shared publications - Stuart J. Conway
University of California, Los Angeles
5 shared publications Deborah Sneddon
Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, UK
3 shared publicationsIshna N. Mistry
Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
3 shared publicationsSalaheddin A. I. Sharif
WestCHEM, School of Chemistry, The Joseph Black Building, University of Glasgow , Glasgow G12 8QQ, United Kingdom
3 shared publications
Latest Publications
- Open Access
- 25 September 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (40) , 36352-36364
Indolequinone-Based Hypoxia-Activated Proteolysis Targeting Chimeras Selectively Degrade BRD4 in Hypoxic Cancer Cells
Proteolysis targeting chimeras (PROTACs) have helped to establish proximity induction as an exciting strategy in drug discovery, and there are multiple clinical trials focused on this modality. However, degradation of a full protein in a physiological setting might lead to dose-limiting toxicities, giving rise to the need for PROTACs that are activated in a context-dependent nature. Here, we report the development of hypoxia-activated PROTACs (HAP-TACs) which are selectively activated in conditions of low oxygen (hypoxia) such as those found in solid tumors. To develop HAP-TACs, we have attached an indolequinone bioreductive group to an essential functional group of either the VHL- or cereblon-recruiting component of the PROTAC, reducing affinity for its cognate E3 ligase and preventing degradation of the protein of interest. Using BRD4, we have conducted proof-of-concept studies which demonstrate that the indolequinone group is bioreduced under hypoxic conditions, releasing the active PROTAC, resulting in selective degradation of BRD4 in hypoxia. As the bioreductive group is attached to the VHL or cereblon ligand, this approach is potentially applicable to all PROTACs that recruit these commonly employed E3 ligases.
- 25 September 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (40) , 36352-36364
Open AccessIndolequinone-Based Hypoxia-Activated Proteolysis Targeting Chimeras Selectively Degrade BRD4 in Hypoxic Cancer Cells
Proteolysis targeting chimeras (PROTACs) have helped to establish proximity induction as an exciting strategy in drug discovery, and there are multiple clinical trials focused on this modality. However, degradation of a full protein in a physiological setting might lead to dose-limiting toxicities, giving rise to the need for PROTACs that are activated in a context-dependent nature. Here, we report the development of hypoxia-activated PROTACs (HAP-TACs) which are selectively activated in conditions of low oxygen (hypoxia) such as those found in solid tumors. To develop HAP-TACs, we have attached an indolequinone bioreductive group to an essential functional group of either the VHL- or cereblon-recruiting component of the PROTAC, reducing affinity for its cognate E3 ligase and preventing degradation of the protein of interest. Using BRD4, we have conducted proof-of-concept studies which demonstrate that the indolequinone group is bioreduced under hypoxic conditions, releasing the active PROTAC, resulting in selective degradation of BRD4 in hypoxia. As the bioreductive group is attached to the VHL or cereblon ligand, this approach is potentially applicable to all PROTACs that recruit these commonly employed E3 ligases.
- Open Access
- 21 June 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Indolequinone-based hypoxia-activated PROTACs (HAP-TACs) selectively degrade BRD4 in hypoxic cancer cells
Proteolysis targeting chimeras (PROTACs) have helped to establish proximity induction as an exciting strategy in drug discovery, and there are multiple clinical trials focused on this modality. However, degradation of a full protein in a physiological setting might lead to dose-limiting toxicities, giving rise to the need for PROTACs that are activated in a context dependent nature. Here we report the development of hypoxia-activated PROTACs (HAP-TACs), which are selectively activated in conditions of low oxygen (hypoxia), such as those found in solid tumors. To develop HAP-TACs, we have attached an indolequinone bioreductive group to an essential functional group of either the VHL- or cereblon-recruiting component of the PROTAC, reducing affinity for its cognate E3 ligase, and preventing protein of interest degradation. Using BRD4, we have conducted proof-of-concept studies, which demonstrate that the indolequinone group is bioreduced in hypoxic conditions releasing the active PROTAC, resulting in selective degradation of BRD4 in hypoxia. As the bioreductive group is attached to the VHL or cereblon ligand, this approach is potentially applicable to all PROTACs that recruit these commonly employed E3 ligases.
- 21 June 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessIndolequinone-based hypoxia-activated PROTACs (HAP-TACs) selectively degrade BRD4 in hypoxic cancer cells
Proteolysis targeting chimeras (PROTACs) have helped to establish proximity induction as an exciting strategy in drug discovery, and there are multiple clinical trials focused on this modality. However, degradation of a full protein in a physiological setting might lead to dose-limiting toxicities, giving rise to the need for PROTACs that are activated in a context dependent nature. Here we report the development of hypoxia-activated PROTACs (HAP-TACs), which are selectively activated in conditions of low oxygen (hypoxia), such as those found in solid tumors. To develop HAP-TACs, we have attached an indolequinone bioreductive group to an essential functional group of either the VHL- or cereblon-recruiting component of the PROTAC, reducing affinity for its cognate E3 ligase, and preventing protein of interest degradation. Using BRD4, we have conducted proof-of-concept studies, which demonstrate that the indolequinone group is bioreduced in hypoxic conditions releasing the active PROTAC, resulting in selective degradation of BRD4 in hypoxia. As the bioreductive group is attached to the VHL or cereblon ligand, this approach is potentially applicable to all PROTACs that recruit these commonly employed E3 ligases.
- Open Access
- 19 December 2024
- Published by Springer Nature in Communications Chemistry
- Vol. 7 (1) , 1-10
Discovering covalent cyclic peptide inhibitors of peptidyl arginine deiminase 4 (PADI4) using mRNA-display with a genetically encoded electrophilic warhead
Covalent drugs can achieve high potency with long dosing intervals. However, concerns remain about side-effects associated with off-target reactivity. Combining macrocyclic peptides with covalent warheads provides a solution to minimise off-target reactivity: the peptide enables highly specific target binding, positioning a weakly reactive warhead proximal to a suitable residue in the target. Here we demonstrate the direct discovery of covalent cyclic peptides using encoded libraries containing a weakly electrophilic cysteine-reactive fluoroamidine warhead. We combine direct incorporation of the warhead into peptide libraries using the flexible in vitro translation system with a peptide selection approach that identifies only covalent target binders. Using this approach, we identify potent and selective covalent inhibitors of the peptidyl arginine deiminase, PADI4 or PAD4, that react exclusively at the active site cysteine. We envisage this approach will enable covalent peptide inhibitor discovery for a range of related enzymes and expansion to alternative warheads in the future.
- 19 December 2024
- Published by Springer Nature in Communications Chemistry
- Vol. 7 (1) , 1-10
Open AccessDiscovering covalent cyclic peptide inhibitors of peptidyl arginine deiminase 4 (PADI4) using mRNA-display with a genetically encoded electrophilic warhead
Covalent drugs can achieve high potency with long dosing intervals. However, concerns remain about side-effects associated with off-target reactivity. Combining macrocyclic peptides with covalent warheads provides a solution to minimise off-target reactivity: the peptide enables highly specific target binding, positioning a weakly reactive warhead proximal to a suitable residue in the target. Here we demonstrate the direct discovery of covalent cyclic peptides using encoded libraries containing a weakly electrophilic cysteine-reactive fluoroamidine warhead. We combine direct incorporation of the warhead into peptide libraries using the flexible in vitro translation system with a peptide selection approach that identifies only covalent target binders. Using this approach, we identify potent and selective covalent inhibitors of the peptidyl arginine deiminase, PADI4 or PAD4, that react exclusively at the active site cysteine. We envisage this approach will enable covalent peptide inhibitor discovery for a range of related enzymes and expansion to alternative warheads in the future.
- Open Access
- 1 September 2021
- Published by Elsevier in Cell Chemical Biology
- Vol. 28 (9) , 1258-1270.e13
Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor
- 1 September 2021
- Published by Elsevier in Cell Chemical Biology
- Vol. 28 (9) , 1258-1270.e13
Open AccessDevelopment and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor
- Open Access
- 14 July 2021
- Published by Wiley in ChemMedChem
- Vol. 16 (24) , 3691-3700
Zap‐Pano: a Photocaged Prodrug of the KDAC Inhibitor Panobinostat
We report the synthesis and biological evaluation of a light‐activated (caged) prodrug of the KDAC inhibitor panobinostat (Zap‐Pano). We demonstrate that addition of the 4,5‐dimethoxy‐2‐nitrobenzyl group to the hydroxamic acid oxygen results in an inactive prodrug. In two cancer cell lines we show that photolysis of this compound releases panobinostat and an unexpected carboxamide analogue of panobinostat. Photolysis of Zap‐Pano causes an increase in H3K9Ac and H3K18Ac, consistent with KDAC inhibition, in an oesophageal cancer cell line (OE21). Irradiation of OE21 cells in the presence of Zap‐Pano results in apoptotic cell death. This compound is a useful research tool, allowing spatial and temporal control over release of panobinostat.
- 14 July 2021
- Published by Wiley in ChemMedChem
- Vol. 16 (24) , 3691-3700
Open AccessZap‐Pano: a Photocaged Prodrug of the KDAC Inhibitor Panobinostat
We report the synthesis and biological evaluation of a light‐activated (caged) prodrug of the KDAC inhibitor panobinostat (Zap‐Pano). We demonstrate that addition of the 4,5‐dimethoxy‐2‐nitrobenzyl group to the hydroxamic acid oxygen results in an inactive prodrug. In two cancer cell lines we show that photolysis of this compound releases panobinostat and an unexpected carboxamide analogue of panobinostat. Photolysis of Zap‐Pano causes an increase in H3K9Ac and H3K18Ac, consistent with KDAC inhibition, in an oesophageal cancer cell line (OE21). Irradiation of OE21 cells in the presence of Zap‐Pano results in apoptotic cell death. This compound is a useful research tool, allowing spatial and temporal control over release of panobinostat.
- Open Access
- 8 December 2020
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 2 (1) , 151-165
Strategies to expand peptide functionality through hybridisation with a small molecule component
This review details discovery strategies and established applications of peptide-small molecule hybrids, classified by the added functionality imparted by the small molecule component.
- 8 December 2020
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 2 (1) , 151-165
Open AccessStrategies to expand peptide functionality through hybridisation with a small molecule component
This review details discovery strategies and established applications of peptide-small molecule hybrids, classified by the added functionality imparted by the small molecule component.
- 1 May 2020
- Published by Elsevier in Tetrahedron
- Vol. 76 (21)
Hypoxia-activated pro-drugs of the KDAC inhibitor vorinostat (SAHA)
- 1 May 2020
- Published by Elsevier in Tetrahedron
- Vol. 76 (21)
Hypoxia-activated pro-drugs of the KDAC inhibitor vorinostat (SAHA)
- Open Access
- 16 October 2017
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 82 (21) , 11585-11593
One-Pot Asymmetric Synthesis of Alkylidene 1-Alkylindan-1-ols Using Brønsted Acid and Palladium Catalysis
A one-pot catalytic enantioselective allylboration/Mizoroki-Heck reaction of 2-bromoaryl ketones has been developed for the asymmetric synthesis of 3-methyleneindanes bearing a tertiary alcohol center. Brønsted acid catalyzed allylboration with a chiral BINOL derivative was followed by a palladium-catalyzed Mizoroki-Heck cyclization, resulting in selective formation of the exo-alkene. This novel protocol provides a concise and scalable approach to 1-alkyl-3-methyleneindan-1-ols in high enantiomeric ratios (up to 96:4 er). The potential of these compounds as chiral building blocks was demonstrated with efficient transformation to optically active diol and amino alcohol scaffolds.
- 16 October 2017
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 82 (21) , 11585-11593
Open AccessOne-Pot Asymmetric Synthesis of Alkylidene 1-Alkylindan-1-ols Using Brønsted Acid and Palladium Catalysis
A one-pot catalytic enantioselective allylboration/Mizoroki-Heck reaction of 2-bromoaryl ketones has been developed for the asymmetric synthesis of 3-methyleneindanes bearing a tertiary alcohol center. Brønsted acid catalyzed allylboration with a chiral BINOL derivative was followed by a palladium-catalyzed Mizoroki-Heck cyclization, resulting in selective formation of the exo-alkene. This novel protocol provides a concise and scalable approach to 1-alkyl-3-methyleneindan-1-ols in high enantiomeric ratios (up to 96:4 er). The potential of these compounds as chiral building blocks was demonstrated with efficient transformation to optically active diol and amino alcohol scaffolds.
- Open Access
- 1 August 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 98 (5) , 1183-1196
Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy
- 1 August 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 98 (5) , 1183-1196
Open AccessClinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy
- Open Access
- 16 December 2016
- Published by Wiley in Chemistry – A European Journal
- Vol. 23 (5) , 1044-1047
Intermolecular Aryl C−H Amination through Sequential Iron and Copper Catalysis
A mild, efficient and regioselective method for para‐amination of activated arenes has been developed through a combination of iron and copper catalysis. A diverse range of products were obtained from an operationally simple one‐pot, two‐step procedure involving bromination of the aryl substrate with the powerful Lewis acid iron(III) triflimide, followed by a copper(I)‐catalysed N‐arylation reaction. This two‐step dehydrogenative process for the regioselective coupling of aromatic C−H bonds with non‐activated amines was applicable to anisole‐, phenol‐, aniline‐ and acetanilide‐type aryl compounds. Importantly, the arene substrates were used as the limiting reagent and required no protecting‐group manipulations during the transformation.
- 16 December 2016
- Published by Wiley in Chemistry – A European Journal
- Vol. 23 (5) , 1044-1047
Open AccessIntermolecular Aryl C−H Amination through Sequential Iron and Copper Catalysis
A mild, efficient and regioselective method for para‐amination of activated arenes has been developed through a combination of iron and copper catalysis. A diverse range of products were obtained from an operationally simple one‐pot, two‐step procedure involving bromination of the aryl substrate with the powerful Lewis acid iron(III) triflimide, followed by a copper(I)‐catalysed N‐arylation reaction. This two‐step dehydrogenative process for the regioselective coupling of aromatic C−H bonds with non‐activated amines was applicable to anisole‐, phenol‐, aniline‐ and acetanilide‐type aryl compounds. Importantly, the arene substrates were used as the limiting reagent and required no protecting‐group manipulations during the transformation.